利福昔明在肝硬化相关并发症中的应用

吕新月; 李磊

doi:10.3969/j.issn.1001-5256.2018.07.040

利福昔明在肝硬化相关并发症中的应用

DOI: 10.3969/j.issn.1001-5256.2018.07.040

吕新月,
李磊

首都医科大学附属北京佑安医院肝病消化中心

基金项目:

北京市卫生系统高层次卫生技术人才培养计划(2013-3-073)；北京市扬帆计划(感染消化内科重点专业ZYLX201610)；登峰计划专项(DFL20151602)；首都发展基金专项(2014-1-2181)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1630
- HTML全文浏览量: 30
- PDF下载量: 335
- 被引次数: 0
出版历程
- 收稿日期: 2018-01-11
- 出版日期: 2018-07-20

Clinical effect of rifaximin in treatment of complications associated with liver cirrhosis

Lu: XinYue,
Li Lei

Department of Gastroenterology and Hepatology, Beijing You An Hospital, Capital Medical University

Research funding:

摘要

摘要: 肝硬化患者往往死于其并发症,其中肝性脑病是肝硬化最常见的死亡原因,而上消化道出血为肝硬化最常见的并发症。近年来随着肝硬化肠道菌群及炎症反应的相关研究的不断进展,一种肠道选择性的口服抗菌药物利福昔明在肝硬化患者中的应用引起了国内外的普遍关注。分析了近年来利福昔明在肝硬化相关并发症中应用的研究,以期对该方向的后续研究及临床实践提供一些合理性的建议。
- 利福昔明 /
- 肝硬化 /
- 肝性脑病 /
- 综述
Abstract: Patients with liver cirrhosis often die of complications, among which hepatic encephalopathy is the primary cause of death and upper gastrointestinal bleeding is the most common complication of liver cirrhosis. In recent years, with the continuous progress in the research on intestinal flora and inflammatory response in patients with liver cirrhosis, rifaximin, a selective oral antibacterial agent, has attracted more and more attention in China and foreign countries. This article analyzes the studies on rifaximin in the treatment of complications associated with liver cirrhosis, in order to provide reasonable suggestions for subsequent studies and clinical practice.
- rifaximin /
- liver cirrhosis /
- hepatic encephalopathy /
- review

HTML全文

参考文献(36)

[1]TSOCHATZIS EA, BOSCH J, BURROUGHS AK.Liver cirrhosis[J].Lancet, 2014, 383 (9930) :1749-1761.

[2]SHAYTO RH, ABOU MR, SHARARA AI.Use of rifaximin in gastrointestinal and liver diseases[J].World J Gastroenterol, 2016, 22 (29) :6638-6651.

[3]BAJAJ JS, WADE JB, SANYAL AJ.Spectrum of neurocognitive impairment in cirrhosis:Implications for the assessment of hepatic encephalopathy[J].Hepatology, 2009, 50 (6) :2014-2021.

[4]PRASAD S, DHIMAN RK, DUSEJA A, et al.Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy[J].Hepatology, 2007, 45 (3) :549-559.

[5]PATIDAR KR, THACKER LR, WADE JB, et al.Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization[J].Am J Gastroenterol, 2014, 109 (11) :1757-1763.

[6]STEPANOVA M, MISHRA A, VENKATESAN C, et al.In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009[J].Clin Gastroenterol Hepatol, 2012, 10 (9) :1034-1341.

[7]BLEIBEL W, AL-OSAIMI AM.Hepatic encephalopathy[J].Saudi J Gastroenterol, 2012, 18 (5) :301-309.

[8]KAJI K, TAKAYA H, SAIKAWA S, et al.Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity[J].World J Gastroenterol, 2017, 23 (47) :8355-8366.

[9]WU D, WU SM, LU J, et al.Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy:A Meta-analysis[J].Gastroenterol Res Pract, 2013, 2013 (2) :236963.

[10]SHARMA BC, SHARMA P, LUNIA MK, et al.A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy[J].Gastroenterol, 2013, 108 (9) :1458-1463.

[11]BASS NM, MULLEN KD, SANYAL A, et al.Rifaximin treatment in hepatic encephalopathy[J].N Engl J Med, 2010, 362 (12) :1071-1081.

[12]LOGUERCIO C, FEDERICO A, de GIROLAMO V, et al.Cyclic treatment of chronic hepatic encephalopathy with rifaximin.Results of a double-blind clinical study[J].Minerva Gastroenterol Dietol, 2003, 49 (1) :53-62.

[13]ORR JG, CURRIE CJ, BERNI E, et al.The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-alpha[J].Liver Int, 2016, 36 (9) :1295-1303.

[14]MAHARSHI S, SHARMA BC, SRIVASTAVA S, et al.Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed[J].Gut, 2015, 64 (8) :1341-1342.

[15]WILLIAMS R, JAMES OF, WARNES TW, et al.Evaluation of the efficacy and safety of rifaximin in the treatment of HE:A doubleblind, randomized, dose-finding multi-centre study[J].Eur J Gastroenterol Hepatol, 2000, 12 (2) :203-208.

[16]LYON KC, LIKER E, MARTELLO JL, et al.Retrospective crosssectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy[J].J Gastroenterol Hepatol, 2017, 32 (9) :1548-1552.

[17]VLACHOGIANNAKOS J, VIAZIS N, VASIANOPOULOU P, et al.Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis[J].J Gastroenterol Hepatol, 2013, 28 (3) :450-455.

[18]DONG T, ARONSOHN A, GAUTHAM RK, et al.Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis[J].Dig Dis Sci, 2016, 61 (12) :3621-3626.

[19]ELFERT A, ABO AL, SOLIMAN S, et al.Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis[J].Eur J Gastroenterol Hepatol, 2016, 28 (12) :1450-1454.

[20]MOSTAFA T, BADRA G, ABDALLAH M.The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients[J].Turk J Gastroenterol, 2015, 26 (2) :163-169.

[21]HANOUNEH MA, HANOUNEH IA, HASHASH JG, et al.The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis[J].J Clin Gastroenterol, 2012, 46 (8) :709-715.

[22]ASSEM M, ELSABAAWY M.Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites:A prospective randomized openlabel comparative multicenter study[J].Hepatol Int, 2016, 10 (2) :377-385.

[23]GOEL A, RAHIM U, NGUYEN LH, et al.Systematic review with meta-analysis:Rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J].Aliment Pharmacol Ther, 2017, 46 (11-12) :1029-1036.

[24]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J].J Clin Hepatol, 2017, 33 (10) :1847-1863. (in Chinese) 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志, 2017, 33 (10) :1847-1863.

[25]BETRAPLLY NS, GILLEVET PM, BAJAJ JS.Gut microbiome and liver disease[J].Transl Res, 2017, 179:49-59.

[26]PISTIKI A, GALANI I, PYLERIS E, et al.In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth[J].Int J of Antimicrob Agents, 2014, 43 (3) :236.

[27]GAO J, OWYANG C.Rifaximin, gut microbes and mucosal inflammation:Unraveling a complex relationship[J].Gut Microbes, 2014, 5 (4) :571-575.

[28]ODENA G, MIQUEL M, SERAFIN A, et al.Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats[J].World J Gastroenterol, 2012, 18 (17) :2084-2091.

[29]KALAMBOKIS GN, MOUZAKI A, RODI M, et al.Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J].Clin Gastroenterol Hepatol, 2012, 10 (7) :815-818.

[30]KIMER N, PEDERSEN JS, BUSK TM, et al.Rifaximin has no effect on hemodynamics in decompensated cirrhosis:A randomized, double-blind, placebo-controlled trial[J].Hepatology, 2017, 65 (2) :592-603.

[31]KIMER N, PEDERSEN JS, BUSK TM, et al.Rifaximin has minor effects on bacterial composition, inflammation and bacterial translocation in cirrhosis;A randomized trial[J].J Gastroenterol Hepatol, 2018, 33 (1) :307-314.

[32]TANG XJ, ZENG X, XIE WF.Research advances in rifaximin for treatment and prevention of hepatic encephalopathy[J].Chin J Dig, 2015, 35 (2) :138-141. (in Chinese) 唐夏姣, 曾欣, 谢渭芬.利福昔明治疗和预防肝性脑病的研究进展[J].中华消化杂志, 2015, 35 (2) :138-141.

[33]MULLEN KD, SANYAL AJ, BASS NM, et al.Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy[J].Clin Gastroenterol Hepatol, 2014, 12 (8) :1390-1397.

[34]ELTAWIL KM, LARYEA M, PELTEKIAN K, et al.Rifaximin vs conventional oral therapy for hepatic encephalopathy:A meta-analysis[J].World J Gastroenterol, 2012, 18 (8) :767-777.

[35]BAJAJ JS, BARRETT AC, BORTEY E, et al.Prolonged remission from hepatic encephalopathy with rifaximin, results of a placebo crossover analysis[J].Aliment Pharmacol Ther, 2015, 41 (1) :39-45.

[36]REIGADAS E, ALCALA L, GOMEZ J, et al.Breakthrough clostridium difficile infection in cirrhotic patients receiving rifaximin[J].Clin Infect Dis, 2017.[Epub ahead of print]

施引文献

资源附件(0)

访问统计